Plasma levels of survivin-positive-EVs were higher in prostate cancer patients than benign hyperplastic patients and healthy donors, potentially providing an alternative tool to reduce the number of false positives generated by the PSA test. This evidence concerns the gene KLK3 and Familial prostate cancer.